Increase Seen in Cases of Schizophrenia Linked to Cannabis Use Disorder

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Feb. 7, 2025 -- The proportion of incident cases of schizophrenia associated with cannabis use disorder (CUD) almost tripled from the prelegalization to legalization of nonmedical cannabis periods, according to a study published online Feb. 4 in JAMA Network Open.

Daniel T. Myran, M.D., M.P.H., from the Ottawa Hospital Research Institute in Ontario, Canada, and colleagues conducted a population-based cohort study among 13,588,681 people aged 14 to 65 years without a history of schizophrenia to examine changes in the population-attributable risk fraction (PARF) for CUD associated with schizophrenia after liberalization of medical cannabis and legalization of nonmedical cannabis in Canada.

Of the participants, 0.9 percent had CUD. The researchers found that 0.7 percent of individuals in the cohort developed schizophrenia (0.6 percent in the general population and 8.9 percent of those with CUD). From the prelegalization to legalization periods, there was an almost threefold increase in the PARF for CUD associated with schizophrenia from 3.7 to 10.3 percent. The PARF in the postlegalization period varied from 18.9 to 1.8 percent among men aged 19 to 24 years and women aged 45 to 65 years, respectively. Over time, the annual incidence of schizophrenia was stable, while the incidence of psychosis not otherwise specified (NOS) increased from 30.0 to 55.1 per 100,000 individuals in the postlegalization versus the prelegalization periods. During the study, there was a steady increase in the PARF for CUD associated with schizophrenia, with no accelerations observed after cannabis policy changes. After medical cannabis liberalization, increases in the PARF for CUD-associated psychosis NOS accelerated.

"Ongoing research is needed on long-term trends in the incidence of psychotic disorders associated with changes in cannabis policy," the authors write.

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-08 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords